| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
Prediction for response to neoadjuvant chemotherapy (NAC) was evaluated in breast cancers. Our study demonstrated that immune-related 23-gene signature (IRSN-23) in breast cancer tissues before NAC, which was one of the multigene assays, was able to predict pCR after NAC highly accurately. Whereas methylated DNA and high total DNA levels in the serum were not significantly associated with pCR, these two markers were significantly associated with unfavorable prognosis. Baseline MRI morphology also appeared to be a significant predictor for pCR. In addition, the performance of MRI morphology in the combination analyses of other clinicopathological parameters improved better than each parameter alone.
|
